Tag Archives: Phil Nadeau

Cowen & Co. Issues a Buy Rating on Tricida (TCDA)

Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Tricida (TCDA – Research Report) on August 6 and set a price target of $40.00. The company’s shares closed last Friday at $13.74, close to its 52-week low of

Atreca (BCEL) Gets a Buy Rating from Cowen & Co.

In a report issued on June 15, Phil Nadeau from Cowen & Co. maintained a Buy rating on Atreca (BCEL – Research Report). The company’s shares closed last Tuesday at $18.83. According to TipRanks.com, Nadeau is a 5-star analyst with

Cowen & Co. Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report). The company’s shares closed last Monday at $6.02. According to TipRanks.com, Nadeau is a 4-star analyst with an

Cowen & Co. Remains a Buy on Vertex Pharmaceuticals (VRTX)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $260.00. The company’s shares closed last Monday at $232.29. According to TipRanks.com, Nadeau is a 4-star

Cowen & Co. Remains a Buy on Apellis Pharmaceuticals (APLS)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $40.00. The company’s shares closed last Monday at $33.60. According to TipRanks.com, Nadeau

Cowen & Co. Reaffirms Their Buy Rating on Immunomedics (IMMU)

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Immunomedics (IMMU – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $15.67. According to TipRanks.com, Nadeau is